Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Concord Biotech Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.000000
forwardPE 30.130781
debtToEquity 0.088000
earningsGrowth -0.163000
revenueGrowth 0.137000
grossMargins 0.639150
operatingMargins 0.288850
trailingEps 29.770000
forwardEps 37.795240

CONCORDBIO's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
Positive gross and operating margins for Concord Biotech Limited highlight the company's profitability. These metrics reflect Concord Biotech Limited's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
CONCORDBIO's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for CONCORDBIO's financial performance.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

The current price of CONCORDBIO aligns with projections, showing no clear risks or opportunities. This lack of volatility suggests a stable environment for investors, who may wish to hold off on major adjustments until market conditions change.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


With analysts showing a buy bias for Concord Biotech Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Concord Biotech Limited as a safe and profitable place for investors to allocate their funds and seek growth.